MacroGenics to Participate in Upcoming Investor Conferences
March 01 2024 - 5:48PM
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company
focused on developing, manufacturing and commercializing innovative
monoclonal antibody-based therapeutics for the treatment of cancer,
today announced that the Company's management will participate in
the following investor conferences in March 2024:
- TD Cowen’s 44th Annual Health Care Conference
(Boston). MacroGenics’ President & Chief Executive
Officer, Scott Koenig, M.D., Ph.D., will participate in a Prostate
Cancer Corporate Panel Discussion on Monday, March 4, 2024, at
10:30 am ET. MacroGenics’ management will also participate in
one-on-one meetings.
- Leerink Partners 2024 Global Biopharma Conference
(Miami). Scott Koenig, M.D., Ph.D., will participate in a
fireside chat on Tuesday, March 12, 2024, at 9:20 am ET.
MacroGenics’ management will also participate in one-on-one
meetings.
- Barclays 26th Annual Global Healthcare Conference
(Miami). Scott Koenig, M.D., Ph.D., will participate in a
fireside chat on Wednesday, March 13, 2024, at 10:15 am ET.
MacroGenics’ management will also participate in one-on-one
meetings.
Webcasts of the above presentations may be accessed under
"Events & Presentations" in the Investor Relations section of
MacroGenics' website at http://ir.macrogenics.com/events.cfm.
The Company will maintain archived replays of these webcasts on its
website for 30 days after each conference.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused
on developing, manufacturing and commercializing innovative
monoclonal antibody-based therapeutics for the treatment of cancer.
The Company generates its pipeline of product candidates primarily
from its proprietary suite of next-generation antibody-based
technology platforms, which have applicability across broad
therapeutic domains. The combination of MacroGenics' technology
platforms and protein engineering expertise has allowed the Company
to generate promising product candidates and enter into several
strategic collaborations with global pharmaceutical and
biotechnology companies. For more information, please see the
Company's website at www.macrogenics.com. MacroGenics and the
MacroGenics logo are trademarks or registered trademarks of
MacroGenics, Inc.
###
CONTACTS:
Jim Karrels, Senior Vice President, CFO
1-301-251-5172, info@macrogenics.com
MacroGenics (NASDAQ:MGNX)
Historical Stock Chart
From Apr 2024 to May 2024
MacroGenics (NASDAQ:MGNX)
Historical Stock Chart
From May 2023 to May 2024